# Pharmacokinetics and Safety Profile of CKD-333

> **NCT03659149** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 37 (actual)

## Conditions studied

- Hypertension
- Dyslipidemias

## Interventions

- **DRUG:** CKD-333 formulation I
- **DRUG:** CKD-333 formulation II
- **DRUG:** CKD-330+D086

## Key facts

- **NCT ID:** NCT03659149
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-08
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03659149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03659149, "Pharmacokinetics and Safety Profile of CKD-333". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03659149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*